Edgewise Therapeutics Inc (EWTX)
Healthcare
Biotechnology
38.40 $
-0.1%
vs. previous close
Closing price · As of: 3. Aug 2026
Edgewise Therapeutics Inc (EWTX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -144 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| -9.2 | -15 | -34 | -53 | -92 | -109 | -144 | |
| 0.1 | 0.2 | 0.3 | 0.5 | 1.7 | 2.3 | 2.3 | |
| 0.1 | 0.4 | 4.4 | 11 | 18 | 25 | 35 | |
| 0.1 | 0.4 | 4.4 | 11 | – | – | – | |
| 0.3 | 2.0 | 4.6 | 4.1 | -1.6 | 10 | -5.4 | |
| 0.2 | 0.2 | 0.7 | 5.5 | 5.7 | 1.3 | 0.3 | |
| -0.2 | -24 | -242 | -71 | 103 | -185 | -33 | |
| – | – | 186 | 130 | – | – | – | |
| – | – | – | -0.3 | – | – | – | |
| 25 | 120 | 186 | 130 | 53 | 249 | 196 | |
| 15 | 81 | -89 | 6.4 | 64 | -44 | 19 | |
| -9.4 | -15 | -34 | -58 | -98 | -110 | -144 |
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.